After August 17, 2026, Novus Biologicals products and services will no longer be available on this website; you will access all products and services on rndsystems.com. Create your R&D Systems online account today.
210-TA), Recombinant Human IL-18/ IL-1F4 stimulates IFN-gamma secretion in the KG-1 human acute myelogenous leukemia cell line in a dose-dependent manner (left-hand graph), as measured by the Human IFN-gamma Quantikine ELISA Kit (Catalog # DIF50C). Under these conditions, IFN-gamma secretion elicited by Recombinant Human IL-18/ IL-1F4 (40 ng/mL) is neutralized (right-hand graph) by increasing concentrations of Mouse Anti-Human IL-18 R beta /IL-1 R7 Monoclonal Antibody (Catalog # MAB1181). The ND50 is typically 0.3-1.0 µg/mL." class="big_lightbox" target="_blank">
MAB0041, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG F(ab')2Secondary Antibody (Catalog # F0102B)." class="big_lightbox" target="_blank">
816-LR) is coated at 0.500 µg/mL (100 µL/well), Biotinylated Recombinant Human IL‑18R beta /IL‑1R7 His-tag Avi-tag Protein (Catalog # AVI11210) binds with an ED50 of 2.00-40.0 ng/mL." class="big_lightbox" target="_blank">
ACPL is encoded by this gene is an accessory subunit of the heterodimeric receptor for IL18. This protein enhances the IL18 binding activity of IL18R1 (IL1RRP), a ligand binding subunit of IL18 receptor. The coexpression of IL18R1 and this protein is required for the activation of NF-kappaB and MAPK8 (JNK) in response to IL18.